tag glp 
XTalks
NOVEMBER 3, 2022
Demand for Lilly’s GIP/GLP-1 receptor agonist Mounjaro is also rising because of high patient demand since the drug’s May 13 FDA approval and expanding insurance coverage. In contrast, Novo’s diabetes drugs Ozempic and Rybelsus (both semaglutide) are just GLP-1 agonists. In the third quarter of 2022, Mounjaro scored $187.3
XTalks
APRIL 29, 2022
Tirzepatide is a novel investigational obesity treatment that contains mimetics of two hormones that are involved in regulating appetite in a single peptide: a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 agonists were first developed as diabetes treatments.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
JULY 19, 2023
Tags #pctGR, @Collaboratory1 The post Grand Rounds July 14, 2023: Lessons From the COORDINATE-Diabetes Trial (Christopher B. However, these therapies are highly underused in routine clinical practice. How do you elevate the pharmacists to get embedded in the clinics and remain engaged? How do you incentivize patients to see this through?
Pharmaceutical Technology
NOVEMBER 30, 2022
Mounjaro is a combination of the two gut hormones GLP-1 and GIP. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. million in Q3. weight loss in obese or overweight individuals. compared to a 5.1%
Pharmaceutical Technology
NOVEMBER 30, 2022
Mounjaro is a combination of the two gut hormones GLP-1 and GIP. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. million in Q3. weight loss in obese or overweight individuals. compared to a 5.1%
Expert insights. Personalized for you.
98 
Let's personalize your content